Technical Analysis for ACHN - Achillion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.83 -1.05% -0.03
ACHN closed down 1.05 percent on Tuesday, December 12, 2017, on 76 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ACHN trend table...

Date Alert Name Type % Chg
Dec 12 New 52 Week Closing Low Bearish 0.00%
Dec 12 New 52 Week Low Other 0.00%
Dec 12 Wide Bands Range Expansion 0.00%
Dec 12 Oversold Stochastic Weakness 0.00%
Dec 11 New 52 Week Closing Low Bearish -1.05%
Dec 11 New 52 Week Low Other -1.05%
Dec 11 Outside Day Range Expansion -1.05%
Dec 11 Wide Bands Range Expansion -1.05%
Dec 11 Oversold Stochastic Weakness -1.05%
Dec 8 New 52 Week Low Other -2.41%

Older signals for ACHN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on the development of antivirals for the treatment of chronic hepatitis C viral (HCV) infection. The company's drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3 protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; and ACH-2684, a NS3 protease inhibitor, which has completed Phase Ia and 1b clinical trials. Its pipeline of antibacterial product candidates includes ACH-702 for the treatment of dermatologic and ophthalmic infections; and ACH-2881 for the treatment of serious resistant bacterial infections, including methicillin-resistant staphylococcus aureus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Is ACHN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.66
52 Week Low 2.8
Average Volume 1,883,204
200-Day Moving Average 4.0968
50-Day Moving Average 3.7874
20-Day Moving Average 3.178
10-Day Moving Average 2.982
Average True Range 0.1661
ADX 43.52
+DI 9.44
-DI 33.05
Chandelier Exit (Long, 3 ATRs ) 3.4417
Chandelier Exit (Short, 3 ATRs ) 3.2983
Upper Bollinger Band 3.6661
Lower Bollinger Band 2.6899
Percent B (%b) 0.14
BandWidth 30.717432
MACD Line -0.2624
MACD Signal Line -0.2531
MACD Histogram -0.0093
Fundamentals Value
Market Cap 387.03 Million
Num Shares 137 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -5.66
Price-to-Sales 33.83
Price-to-Book 1.40
PEG Ratio -0.32
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.00
Resistance 3 (R3) 3.00 2.96 2.97
Resistance 2 (R2) 2.96 2.91 2.95 2.96
Resistance 1 (R1) 2.89 2.89 2.87 2.89 2.95
Pivot Point 2.85 2.85 2.84 2.84 2.85
Support 1 (S1) 2.78 2.80 2.76 2.78 2.71
Support 2 (S2) 2.74 2.78 2.73 2.70
Support 3 (S3) 2.67 2.74 2.69
Support 4 (S4) 2.67